Search Medical Condition
Please enter condition
Please choose location from dropdown

Donaueschingen, Germany Clinical Trials

A listing of Donaueschingen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

Post Market Observational Prospective Multi-center Study

This registry is a post market observational, prospective, multi-center registry. It is designed to evaluate patient experience with the RePneu device for the relief of the emphysema symptoms and the continued collection of safety and effectiveness data on this CE Mark product. In addition, the registry will collect information that ...

Phase N/A

0.51 miles

Learn More »

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

The purpose of the study is to determine the effect of LCZ696 vs. Enalapril on improvement of excercise capacity in patients with chronic heart failure with reduced ejection fraction

Phase

7.34 miles

Learn More »

Chart Review of Repatha in Subjects With Hyperlipidaemia

Review of clinical characteristics of patients who are prescribed Repatha and how their treatment is managed.

Phase N/A

7.34 miles

Learn More »

AMPLATZER Amulet LAA Occluder Trial

The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN LAA closure ...

Phase N/A

7.34 miles

Learn More »

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint ...

Phase

7.34 miles

Learn More »

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

7.34 miles

Learn More »

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the patient has, and the age of the patient when diagnosed. Venetoclax is an experimental drug that kills ...

Phase

7.34 miles

Learn More »

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

This post authorization safety study is designed as prospective non interventional study for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The objective is to compare the incidence of cardiovascular events between patients treated with a first-line lenalidomide containing regimen and those treated with a first-line ...

Phase N/A

7.34 miles

Learn More »

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 4 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

The primary objective of this current trial is to investigate the safety and tolerability of 4 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor blockers [ARB]. Secondary objective is to evaluate the ...

Phase

7.34 miles

Learn More »

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

The primary objective is to assess the safety and tolerability of sequential therapy consisting of standard of care mono- or combination chemotherapy followed by durvalumab in comparison to standard of care mono- or combination chemotherapy in frail/elderly patients.

Phase

7.34 miles

Learn More »